

MyBreastAI Suite*

One platform.

Powering endless possibilities.



GE HealthCare

Today's challenges

Heavy workloads. Limited staff. You're consistently expected to do more with less. And the growing number of breast cancer cases worldwide only adds to the pressure.

1 in 8 women
will develop breast cancer¹

Incidence rates increasing
5% per year¹

Women with dense breasts
4 to 6 X more
likely to develop breast cancer¹

20-40%
of breast cancers are missed²⁻⁵

77% High prevalence of
burnout among breast imagers⁶⁻⁷

71% Report stress of having
to practice faster than they
would like because of a high
volume of work⁶⁻⁷



One platform. Powering endless possibilities.


MyBreastAI Suite is a one-stop platform of proven AI apps to help accelerate breast cancer detection for peace of mind. Push your productivity with simplicity.

There is enough demand for your time and attention without the added hassle of finding, adopting, and maintaining multiple applications. MyBreastAI Suite offers a comprehensive collection of apps that assist you to personalize breast cancer screening.

MyBreastAI Suite initial release includes:

- ProFound AI® for DBT
- ProFound AI® for 2D
- PowerLook® Density Assessment

 Best-in-class AI tools for breast cancer detection and density assessment

 Simplify with one supplier for integration, training, service, and upgrades



 Tailored to your facility's workflow

Increase sensitivity ProFound AI[®] for DBT

Trained with one of the largest available 3D image datasets, ProFound AI provides radiologists with crucial information, such as lesion Certainty of Finding and Case Scores, which assists in prioritizing caseload, clinical decision-making and may help to reduce physician burnout⁸.

Patient Name	Date of Birth	Case Score	List Description
1001_Pristina 3d24-Calcis-Docs-Left	1/12/1993	100	1001_Pristina 3d24-calcis-docs-left
021_Pristina 3d24_C_Left_Distortion_Mc_Multicentric	3/12/1963	99	021_Pristina 3D2D
064_Pristina 3d24+Cream_C_Left_Distortion Calc_Mc+Docs	9/15/1962	99	064_Pristina 3D2D+CE5M
1023_Pristina 3d24_Microcalc_Docs_Left	--	99	1023_Pristina 3D2D_Microcalc_Docs_Left
1034_Pristina 3d24_Microcalc_Dystrophic_Mass Papilloma_Left	--	99	1034_Pristina 3D2D_Microcalc_Dyst.
Case 02_Pristina 3d24_B_Microcalc	6/15/1973	99	DBT for lesion depth before biopsy_IDC+
062_Pristina 3d24_Hd_C_Right_Spiculated Mass_Microcalc_Mc	--	98	062_Pristina 3d2D_Hd_C_Right_Spicul.
062_Pristina 3d24_C_Right_Spiculated Mass_Microcalc_Mc	--	98	062_Pristina 3D2D
1017_Pristina 3d24_Distortion Radial Scar Left_Microcalc_Docs Rg	6/27/1979	98	1017_Pristina 3D2D_Distortion Radial s.
1033_Pristina 3d24_Microcalc_Docs_Left	--	98	1033_Pristina 3D2D_Microcalc_Docs
1036_Pristina 3d24_Microcalc_Docs_Left	--	97	1036_Pristina 3D2D_Microcalc_Docs
Case 01_Pristina 3d24_C_Distortion Relo_Ic	4/15/1968	41	asymmetry of density on 2D LMLD -DBT
029_Pristina 3d24_C_Right_Cysts_Dystrophic_Microcalc	9/6/1968	40	029_Pristina 3D2D
036_Pristina 3d24_C_Left_Distortion_Mc	6/21/1944	40	036_Pristina 3D2D
005_Pristina 3d24_D_Left_Fibroadenoma	9/28/1967	35	005_Pristina 3D2D
043_Pristina 3d24_D_Right_Distortion_Mc	11/12/1969	34	043_Pristina 3D2D
008_Pristina 3d24_C_Right_Fibroadenoma	8/9/1970	31	008_Pristina 3D2D
1027_Pristina 3d24_Mass Cyst_Left	--	30	1027_Pristina 3D2D_Mass Cyst_Left
021_Pristina 3d24_C_Left_Dystrophic_Microcalc	1/11/1959	25	021_Pristina 3D2D
025_Pristina 3d24_Hd_C_Left_Dystrophic_Microcalc	6/19/1968	25	025_Pristina 3d2D_Hd_C_Left_Distoph.
1036_Pristina 3d24_Mass Lipoma_Left	--	20	1036_Pristina 3D2D_Mass Lipoma_Left
029_Pristina 3d24_C_Left_Cyst	1/27/1974	19	029_Pristina 3D2D
1003_Pristina 3d24-Subtle Spic Mass-Mc-Right	--	19	1003_Pristina 3d24-subtle spic mass-Id.
Whorl_AI_193114333405508	--	19	WHORL_AI_193114333405508

Profound AI's Certainty of Findings scores assist in prioritizing caseload and clinical decision-making¹¹.



Easy navigation between the V-Preview and the slices containing the AI markers.

The iCAD reader study shows that reading with ProFound AI:

By **8%** Increases reader sensitivity by 8%⁹


By **6.9%** Increases reader specificity by 6.9%⁹

Up to **52%** Decreases reading time by up to 52% compared to without¹⁰

Breast cancer detection

ProFound AI[®] for 2D

The ProFound AI[®] for 2D Computer-Aided Detection (CAD) system for mammography is intended to identify and mark regions of interest on screening and diagnostic mammograms from GE HealthCare full-field digital mammography (FFDM) systems to bring them to the attention of the radiologist after an initial reading has been completed.¹⁴



Standardized reportings

PowerLook[®] Density Assessment

Breast density assessment has traditionally been determined by the radiologist's visual assessment, but studies show these can vary - and clinicians may even disagree with their own assessment year to year. This can lead to unnecessary additional imaging, which can increase patient and facility costs¹².



PowerLook Density helps to:

- Standardize breast density assessment and reduce variability across multiple radiologists.¹²
- Simplify and standardize reporting and stratification for clinicians, with results clinicians can rely on.¹³
- Enable clinicians to provide women with accurate and reliable breast density assessments based on AI mammogram analysis.¹³



PowerLook[®] Version: 1
Density Assessment

Patient Demographics
Patient Name: 9008, A&C[®] Falderson, David Marie, Theresa
Patient ID: 20201062060
Patient DOB: 03/20/1962
Accession #: 22054202
Study Date: 08/19/2020 08:47:50 AM

4.1
3.3
d
c
b
a

C

iCAD[®]

Outperform today. Prepare for tomorrow.



Simplify the way you work and experience more opportunities with MyBreastAI Suite.



References:

- * MyBreastAI suite is a commercial offering that includes an AI platform optimized for Mammography, ProFound AI for 2D, ProFound AI for DBT and PowerLook® Density Assessment. These three applications are provided by iCAD. MyBreastAI Suite is compatible with the latest versions of iCAD, Inc. as of November 14, 2023.
1. Arnold M, Morgan E, Rungay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. Current and future burden of breast cancer: Global statistics for 2020 and 2040. *Breast*. 2022 Dec;66:15-23. doi: 10.1016/j.breast.2022.08.010. Epub 2022 Sep 2.
 2. Kalager M, Tamimi R, Bretthauer M et al. Prognosis in women with interval breast cancer: population based observational cohort study. *BMJ*. 2012;345: e7536. doi:10.1136/bmj.e7536.
 3. Marmot M, Altman G, Cameron A et al. The benefits and harms of breast cancer screening: an independent review. *Br J Cancer*. 2013; 108: 11, 2205-2240. doi: 10.1038/bjc.2013.177.
 4. Curry S, Krist A, Owens D. High-priority evidence gaps for clinical preventive services. U.S. Preventive Services Task Force. Published November 2018. Accessed May 11, 2021.
 5. Seely J and Alhassan, T. Screening for breast cancer in 2018—what should we be doing today? *Curr. Oncol*. 2018; 25: S115–S124. doi: 10.3747/co.25.3770.
 6. Parikh JR, Sun J, Mainiero MB. Prevalence of burnout in breast imaging radiologists. *J Breast Imaging*. 2020;2(2):112–116.
 7. Parikh JR, Sun J, Mainiero MB. What Causes the Most Stress in Breast Radiology Practice? A Survey of Members of the Society of Breast Imaging. *J Breast Imaging*. 2021 Apr 19;3(3):332-342. doi: 10.1093/jbi/wbab012.
 8. iCAD data on file. FDA filing: K203822. Standalone performance varies by vendor. FDA Cleared and CE Mark Pending. Reading times may vary based on the specific functionality of the viewing application used for interpretation.
 9. Reader performance with Profound AI compared to performance without. iCAD reader study: Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. *Radiology: Artificial Intelligence*. 1 (4). Accessed via <https://pubs.rsna.org/doi/10.1148/ryai.2019180096> iCAD labelling and user manual, DTM160 rev C.
 10. iCAD reader study: Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. *Radiology: Artificial Intelligence*. 1 (4). Accessed via <https://pubs.rsna.org/doi/10.1148/ryai.2019180096> iCAD labelling and user manual, DTM160 rev C. Reading times may vary based on the specific functionality of the viewing application used for interpretation.
 11. iCAD data on file. FDA filing: K203822. Standalone performance varies by vendor. FDA Cleared and CE Mark Pending. Reading times may vary based on the specific functionality of the viewing application used for interpretation.
 12. Sprague B, Conant E, Omega T et al. Variation in Mammographic Breast Density Assessments Among Radiologists in Clinical Practice: A Multicenter Observational Study. *Ann Intern Med*. 2016; 165(7):457-464. doi:10.7326/M15-2934.
 13. iCAD labelling and user manual, DTM135-1, DTM156 -3, DTM184 rev1.
 14. iCAD labelling and user manual, DTM103 - Revision C.
 15. Pristina Bright is a commercial offering that includes Senographe Pristina™, SenoBright™ HD and Serena Bright™.
 16. With a service contract.
- Product may not be available in all countries and regions. Full product technical specification is available upon request.

About GE HealthCare

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient's journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from prevention and screening, to diagnosis, treatment, therapy, and monitoring. We are an \$18 billion business with 51,000 employees working to create a world where healthcare has no limits.

Follow us on Facebook, LinkedIn, X, Instagram and Insights for the latest news, or visit our website [gehealthcare.com](https://www.gehealthcare.com) for more information.



© 2024 GE HealthCare.

GE is a trademark of General Electric Company used under trademark license.

iCAD, ProFound AI and PowerLook are trademarks of iCAD, Inc.

JB07196XE